Trial · NCT03458325

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

NCT03458325, Phase 3, Completed, scPharmaceuticals, Inc.; results first posted 2023-02-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure. Trials, record NCT03458325. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03458325

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
NCT number: NCT03458325
Status: Completed
Phases: Phase 3
Enrollment: 27 participants, actual
Lead sponsor: scPharmaceuticals, Inc.
Conditions: Heart Failure
Interventions: Furoscix Infusor
First posted: 2018-03-08
Last updated: 2023-02-24
Results first posted: 2023-02-24

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Healthcare Utilization Costs	Day 0 - Day 30	The difference in the overall and heart failure related healthcare costs between subjects treated with the Furoscix Infusor through 30 days post discharge from the emergency department compared to matched controls treated in the hospital for ≤ 72 hours through 30 days post discharge.
Secondary	Heart-Failure Related Hospital Admissions	Day 0 - Day 30	The HF-related admissions for the Furoscix patients compared to Control patients.
Secondary	All-Cause Hospital Admissions	Day 0 - Day 30	The differences in the percentage of subjects with an all-cause hospitalization in the Furoscix group and all-cause 30-day rehospitalization in the Control group in the 30 day follow-up period
Secondary	Heart-Failure Related Emergency Department Visits	Day 0 - Day 30	The differences in the percentage of patients with HF-related emergency department visits in the Furoscix group and in the Control group in the 30 day follow-up period
Secondary	Heart-Failure Related Clinic Visits	Day 0 - Day 30	The differences in the percentage of patients with HF-related clinic visits in the Furoscix group and in the Control group in the 30 day follow-up period
Secondary	KCCQ-12 Scores	30 Days	The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures a patient's self-reported overall health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL). The KCCQ-12 overall summary score is the sum of responses from all 12 items ranging from 0 to 100 with higher scores to indicate better health status.
Secondary	Mean Change in NT-proBNP and BNP	Day 0 - Day 30	Change in NT-proBNP and BNP change from baseline during the study period is summarized for the Furoscix group
Secondary	Comfort of Wear Questionnaire	Day 0 - Day 2-4 study visit	The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
Secondary	Comfort of Wear Questionnaire: Interference With Activities Daily Living	Day 0 - Day 2-4 study visit	The Furoscix group was administered a Comfort of Wear Questionnaire on Day 2-4. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
Secondary	Comfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction	Day 0 - Day 2-4 study visit	The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Healthcare Utilization Costs	Day 0 - Day 30		US Dollars	MEAN
SECONDARY	Heart-Failure Related Hospital Admissions	Day 0 - Day 30	Evaluable Population:	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	All-Cause Hospital Admissions	Day 0 - Day 30	Evaluable Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Heart-Failure Related Emergency Department Visits	Day 0 - Day 30	Evaluable Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Heart-Failure Related Clinic Visits	Day 0 - Day 30		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	KCCQ-12 Scores	30 Days	Summary Score represents integration of Physical Limitation, Symptom Frequency, Quality of Life and Social Limitation Scores. Missing values were not included in this analysis	score on a scale	MEAN
SECONDARY	Mean Change in NT-proBNP and BNP	Day 0 - Day 30	Evaluable Population. Subjects who are missing the NT-proBNP and BNP test results were excluded from this analysis.	pg/ml	MEAN
SECONDARY	Comfort of Wear Questionnaire	Day 0 - Day 2-4 study visit	Evaluable Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Comfort of Wear Questionnaire: Interference With Activities Daily Living	Day 0 - Day 2-4 study visit	Evaluable Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Comfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction	Day 0 - Day 2-4 study visit	Evaluable Population	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group121

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Healthcare Utilization Costs	Furoscix Infusor Prospective Treatment	HF-related healthcare costs	2920.30	Standard Deviation 7073.20	US Dollars
Healthcare Utilization Costs	Furoscix Infusor Prospective Treatment	Overall healthcare costs	7512.30	Standard Deviation 11,905.50	US Dollars
Heart-Failure Related Hospital Admissions	Furoscix Infusor Prospective Treatment		1		Participants
All-Cause Hospital Admissions	Furoscix Infusor Prospective Treatment		6		Participants
Heart-Failure Related Emergency Department Visits	Furoscix Infusor Prospective Treatment		1		Participants
Heart-Failure Related Emergency Department Visits	Matched Historical Control		4		Participants
Heart-Failure Related Clinic Visits	Furoscix Infusor Prospective Treatment		24		Participants
KCCQ-12 Scores	Furoscix Infusor Prospective Treatment - Baseline	Summary Score	29.9	Standard Deviation 22.8	score on a scale
KCCQ-12 Scores	Furoscix Infusor Prospective Treatment - Day 30	Summary Score	42.8	Standard Deviation 28.4	score on a scale
KCCQ-12 Scores	Furoscix Infusor Prospective Treatment - Baseline	Physical Limitation Score	37.1	Standard Deviation 30.1	score on a scale

1 to 10 of 121Source ClinicalTrials.gov

See all 121 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Furoscix Infusor Prospective Treatment	25
Overall Study	COMPLETED	Furoscix Infusor Prospective Treatment	24
Overall Study	NOT COMPLETED	Furoscix Infusor Prospective Treatment	1

Source ClinicalTrials.gov

Adverse events15

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Infusion Site Hemorrhage	General disorders	Furoscix Infusor Prospective Treatment	2	24
other	Infusion Site Bruising	General disorders	Furoscix Infusor Prospective Treatment	7	24
other	Infusion Site Pain	General disorders	Furoscix Infusor Prospective Treatment	7	24
other	Muscle Spasms	Musculoskeletal and connective tissue disorders	Furoscix Infusor Prospective Treatment	2	24
other	Urinary Tract Infection	Infections and infestations	Furoscix Infusor Prospective Treatment	2	24
other	Dizziness	Nervous system disorders	Furoscix Infusor Prospective Treatment	3	24
serious	Cardiac Failure Congestive	Cardiac disorders	Furoscix Infusor Prospective Treatment	1	24
serious	Food Poisoning	Gastrointestinal disorders	Furoscix Infusor Prospective Treatment	1	24
serious	Tibia Fracture	Injury, poisoning and procedural complications	Furoscix Infusor Prospective Treatment	1	24
serious	Diabetic Ketoacidosis	Metabolism and nutrition disorders	Furoscix Infusor Prospective Treatment	1	24

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Furoscix Infusor Prospective Treatment	0	24
Total, other adverse events	Furoscix Infusor Prospective Treatment	18	24
Total, serious adverse events	Furoscix Infusor Prospective Treatment	6	24

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Furoscix Infusor Prospective Treatment vs Matched Historical Control: Heart-Failure Related Emergency Department Visits

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03458325

GET https://conductscience.org/api/trials/v1/NCT03458325/results?page=2

API reference For AI assistants